Economic and clinical outcomes among patients with cholangiocarcinoma receiving pemigatinib with or without history of cancer of unknown primary
Although pemigatinib was similarly well-tolerated regardless of CUP status, patients with CUP incurred greater ambulatory burden and had poorer OS. Patients with CUP were more likely to have evidence of metastatic disease at pemigatinib initiation, which may help explain these results. With the advent of targeted treatments for gene-altered CCA, reflexive genomic testing should be encouraged for all patients with CUP.
Authors
- Nicole Engel-Nitz
- Michael Blecker
- Shreekant Parasuraman (ORCID: https://orcid.org/0000-0001-8162-8171)
- Christina Steiger (ORCID: https://orcid.org/0000-0001-8062-5999)
- Sunyoung S. Lee (ORCID: https://orcid.org/0000-0002-5954-5991)
- Sumit Verma (ORCID: https://orcid.org/0000-0003-1992-4556)
- Fen Saj (ORCID: https://orcid.org/0000-0003-0102-1789)
- Alejandro Hughes (ORCID: https://orcid.org/0000-0002-4608-4217)
- Milind Javle
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Optum (United States) (US)
- Incyte (United States) (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1093/oncolo/oyaf352
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Incyte